Aura Biosciences (AURA) SVP Amy Elazzouzi Receives RSU/Option Award

What Happened

• Amy Elazzouzi, Senior Vice President, Finance & PAO of Aura Biosciences (AURA), received equity awards on 2026-09-01 totaling 70,000 units: 23,540 restricted stock units (RSUs) and 46,460 derivative awards. Both grants were reported at $0.00 per share (typical for compensation awards) and therefore show no cash purchase or sale.

Key Details

• Transaction date: 2026-09-01; Filing date: 2026-09-01 (timely).
• Award amounts: 23,540 RSUs (non-derivative) and 46,460 reported as derivative awards (total = 70,000).
• Reported price: $0.00 per share for both entries (award/grant).
• Shares owned after transaction: not specified in the provided filing details.
• Footnotes:
  • F1: The 23,540 RSUs convert to one share each upon vesting and vest in four substantially equal annual installments; first tranche vests on September 15, 2027.
  • F2: The 46,460 derivative award is a stock option that vests monthly at 1/48th of the total award, with the first tranche vesting on October 1, 2026.
• No indication of a 10b5-1 plan, tax-withholding sale, or late filing in the report.

Context

• RSU grants and option awards are standard compensation tools; they vest over time and do not represent an immediate open-market purchase or sale. The derivative portion is a stock option per the footnote and will deliver value only as it vests and, if applicable, is exercised. These grants signal compensation alignment with company performance rather than an immediate insider market view.